Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study
Language English Country United States Media print-electronic
Document type Journal Article, Multicenter Study
PubMed
31054899
DOI
10.1016/j.humpath.2019.04.014
PII: S0046-8177(19)30079-6
Knihovny.cz E-resources
- Keywords
- Diagnostic biomarker, Endometrial carcinoma, IMP3, L1CAM, Prognostic biomarker,
- MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Neural Cell Adhesion Molecule L1 analysis biosynthesis MeSH
- Biomarkers, Tumor analysis MeSH
- Endometrial Neoplasms pathology MeSH
- RNA-Binding Proteins analysis biosynthesis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Sensitivity and Specificity MeSH
- Neoplasm Grading methods MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Names of Substances
- IGF2BP3 protein, human MeSH Browser
- L1CAM protein, human MeSH Browser
- Neural Cell Adhesion Molecule L1 MeSH
- Biomarkers, Tumor MeSH
- RNA-Binding Proteins MeSH
Discrimination between low- and high-grade endometrial carcinomas (ECs) is clinically relevant but can be challenging for pathologists, with moderate interobserver agreement. Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is an oncofoetal protein that is associated with nonendometrioid endometrial carcinomas but has been limited studied in endometrioid carcinomas. The aim of this study is to investigate the diagnostic and prognostic value of IMP3 in the discrimination between low- and high-grade ECs and its added value to L1CAM. IMP3 and L1CAM expression was assessed in tumors from 378 patients treated for EC at 1 of 9 participating European Network for Individualised Treatment of Endometrial Cancer centers. IMP3 was expressed in 24.6% of the tumors. In general, IMP3 was more homogeneously expressed than L1CAM. IMP3 expression was significantly associated with advanced stage, nonendometrioid histology, grade 3 tumors, deep myometrial invasion, lymphovascular space invasion, distant recurrences, overall mortality, and disease-related mortality. Simultaneous absence of IMP3 and L1CAM expression showed the highest accuracy for identifying low-grade carcinomas (area under the curve 0.766), whereas simultaneous expression of IMP3 and L1CAM was strongly associated with high-grade carcinomas (odds ratio 19.7; 95% confidence interval 9.2-42.2). Even within endometrioid carcinomas, this combination remained superior to IMP3 and L1CAM alone (odds ratio 8.6; 95% confidence interval 3.4-21.9). In conclusion, IMP3 has good diagnostic value and together with L1CAM represents the optimal combination of diagnostic markers for discrimination between low- and high-grade ECs compared to IMP3 and L1CAM alone. Because of the homogenous expression of IMP3, this marker might be valuable in preoperative biopsies when compared to the more patchy L1CAM expression.
Department of Obstetrics and Gynaecology Hospital del Mar 8003 Barcelona Spain
Department of Pathology Canisius Wilhelmina Hospital 6500 GS Nijmegen the Netherlands
Department of Pathology Ghent University Hospital 9000 Ghent Belgium
Department of Pathology Hospital del Mar 8003 Barcelona Spain
Department of Pathology Radboud University Medical Centre 6500HB Nijmegen the Netherlands
Department of Pathology University of Turku 20500 Turku Finland
Obstetrics and Gynaecology Department Bichat Claude Bernard Hospital 75877 Paris France
Pathology Department Bichat Claude Bernard Hospital 75877 Paris France
Pathology Department Vall Hebron University Hospital 8035 Barcelona Spain
References provided by Crossref.org
